Guggenheim raised the firm’s price target on Vera Therapeutics to $56 from $27 and keeps a Buy rating on the shares. The IgA nephropathy, or IgAN, treatment market has seen “significant progress in recent years,” says the analyst, whose updated view of the IgAN market is supported by multiple conversations with leading nephrologists and reflects this perspective. Based on the talks and the firm’s analysis, the firm has increased sales estimates for Vera’s atacicept, the analyst noted.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERA:
- Vera Therapeutics price target raised to $34 from $21 at Wedbush
- Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
- Vera Therapeutics reports FY23 EPS ($2.25) vs ($3.35) last year
- VERA Upcoming Earnings Report: What to Expect?
- Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference
